ARTICLES BY MATTHEW PILLAR
- Clinical Logistics: Keeping COVID-19 Vaccine, Therapeutic Dev On The Rails
- Is Your Definition Of Quality Culture The Same As The FDA's?
- The Biopharma Supply Chain Under The Biden Administration
- Inside AVROBIO’s Approach To Gene Therapy Manufacturing Automation
- Pursuing A Microbial Therapeutic Modality
- 3 Keys To Biopharma Finance Leadership
- COVID-19 Consortium: Competitive Collab On A Plasma-Derived Therapy
- AGTC Goes Mobile To Avoid Clinical Trial Chaos
- Next Steps For AI, Machine Learning In Biopharma
- Inside Wugen’s Off-The-Shelf CAR T Mission
- What’s Process Intensification In Practice?
- 8 Biotech Startup Lessons From Heat Bio’s Jeff Wolf
- Can Valneva Do What SmithKlineBeecham Couldn’t?
- An Inhalable mAb For COVID-19?
- How Ancient Fish DNA Could Contribute To Cancer Therapy
- 4 Tips For Biotech Financing From Afar
- HQ Move Fuels Fountain’s AI Drug Discovery Machine
- Biosensors & Big Data: Implications For Biologics Developers
- COVID-19 Vaccine: Does Small Biopharma Have A Chance?
- Genetically Engineering An IL-15 Superagonist
- Dr. Gaurav Shah’s 4 Keys To Biotech Leadership
- Are Dry Powder Biologics Ready For Primetime?
- IP & Patent Protection At The Perilous Pace Of Biopharma
- Gene Therapy Development Crosses A Digital Divide
- Does RNAi Have A Future Beyond Liver Disease?
This website uses cookies to ensure you get the best experience on our website. Learn more